
Claims:

1. A pharmaceutical composition, comprising:

   (a) at least 10% w/w of a compound of Formula I, wherein Formula I is represented by:



   or a pharmaceutically acceptable salt thereof;

   (b) at least 40% w/w microcrystalline cellulose;

   (c) at least 10% w/w pregelatinized starch;

   (d) at least 2% w/w croscarmellose or a pharmaceutically acceptable salt thereof; and

   (e) at least 0.75% w/w stearic acid or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises from 45% to 65% w/w microcrystalline cellulose.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises from 50% to 56% w/w microcrystalline cellulose.

4. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutical composition comprises at least 20% w/w pregelatinized starch.

5. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutical composition comprises from 15% to 25% w/w pregelatinized starch.

6. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutical composition comprises from 18% to 22% w/w pregelatinized starch.

7. The pharmaceutical composition of any one of claims 1-6, wherein the pharmaceutical composition comprises from 3% w/w to 5% w/w croscarmellose or a pharmaceutically acceptable salt thereof.

8. The pharmaceutical composition of any one of claims 1-7, wherein the croscarmellose or a pharmaceutically acceptable salt thereof is croscarmellose sodium.

9. The pharmaceutical composition of any one of claims 1-8, wherein the pharmaceutical composition comprises from 1% to 2% w/w of stearic acid or a pharmaceutically acceptable salt thereof.


10. The pharmaceutical composition of any one of claims 1-9, wherein the stearic acid or a pharmaceutically acceptable salt thereof is an alkaline earth metal salt of stearic acid.

11. The pharmaceutical composition of any one of claims 1-9, wherein the stearic acid or a pharmaceutically acceptable salt thereof is magnesium stearate.


12. The pharmaceutical composition of any one of claims 1-11, wherein the pharmaceutical composition comprises at least 20% w/w of a compound of Formula I.

13. The pharmaceutical composition of any one of claims 1-11, wherein the pharmaceutical composition comprises from 18% to 24% w/w of a compound of Formula I.

14. The pharmaceutical composition of any one of claims 1-11, wherein the pharmaceutical composition comprises from 20% to 22% w/w of a compound of Formula I.


15. The pharmaceutical composition of any one of claims 1-14, wherein the compound of Formula I is a tartaric acid salt of 

.

16. The pharmaceutical composition of any one of claims 1-14, wherein the compound of Formula I is a D-tartaric acid salt of 

.

17. A pharmaceutical composition, comprising:

(a) from 17% w/w to 25% w/w of a compound of Formula I, wherein Formula I is a D-tartaric acid salt of  ;

(b) from 51% to 56% w/w microcrystalline cellulose;

(c) about 20% w/w pregelatinized starch;

(d) about 4% w/w croscarmellose sodium; and

(e) about 1.5% w/w magnesium stearate.


18. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition comprises from 20% w/w to 22% w/w of the compound of Formula I.

19. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition comprises about 21% w/w of the compound of Formula I.

20. The pharmaceutical composition of any one of claims 17-19, wherein the pharmaceutical composition comprises from 53% to 54% w/w microcrystalline cellulose.

21. The pharmaceutical composition of any one of claims 17-19, wherein the pharmaceutical composition comprises 53% w/w microcrystalline cellulose.

22. A pharmaceutical composition, comprising:

(a) at least 10% w/w of a compound of Formula I, wherein Formula I is represented by:  or a pharmaceutically acceptable salt thereof; and


(b) at least 60% w/w of a diluent selected from microcrystalline cellulose, pregelatinized starch, or a combination thereof.

23. A tablet for oral administration, comprising a pharmaceutical composition of any one of claims 1-22.

24. A method of preparing a pharmaceutical composition, comprising the steps of:

(i) providing a first mixture comprising:

(a) at least 10% w/w of a compound of Formula I, wherein Formula I is represented by:



or a pharmaceutically acceptable salt thereof;

(b) at least 40% w/w microcrystalline cellulose;

(c) at least 10% w/w pregelatinized starch;

(d) at least 2% w/w croscarmellose or a pharmaceutically acceptable salt thereof; and

(e) at least 0.75% w/w stearic acid or a pharmaceutically acceptable salt thereof;

(ii) subjecting the first mixture to roller compaction to produce a compacted mixture; and

(iii) subjecting the compacted mixture to compressive force to produce a compressed pharmaceutical composition.

25. Use of a pharmaceutical composition of any one of claims 1-22 in the manufacture of a medicament for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).

26. The use according to claim 25, wherein said disease or condition mediated by NSD2 is selected from a solid tumor, leukemia, myeloma, lymphoma, and hypertension.

27. The use according to claim 25, wherein said disease or condition mediated by NSD2 is myeloma.

28. Use of a pharmaceutical composition of any one of claims 1-22 in the manufacture of a medicament for inhibiting the activity of nuclear SET domain-containing protein 2 (NSD2).